Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale - Top-Institutions - MDSpire

Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale

  • By

  • Luca Massimino

  • Virginia Solitano

  • Federica Ungaro

  • September 23, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Fibrosis Research

  • #2

    Mount Sinai Hospital - Icahn School of Medicine
    Mount Sinai Hospital - Icahn School of Medicine

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Molecular Medicine

  • #3

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Preclinical Models

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Inflammatory Bowel Disease
    • Fibrosis and Immunology

Original Source(s)

Repurposing losartan for fibrostenosing Crohn’s disease: a compelling preclinical rationale

  • by Luca Massimino, Virginia Solitano, Federica Ungaro

  • September 23, 2025

Related Content

Case Report: Bilateral panuveitis with serous ciliary body and choroidal detachment associated with ulcerative colitis

Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease

Mortality trends from colorectal pathologies in the United States (1999–2020): a retrospective cohort study using CDC WONDER